Laurus Labs Q1 FY27 results: key dates, forex tailwind

What investors are tracking ahead of July 24

Laurus Labs heads into its Q1 FY27 results with attention firmly on its Contract Development and Manufacturing Organization (CDMO) segment and the currency backdrop for exporters. The company has indicated strong momentum in CDMO, while the rupee’s 12-14% year-on-year depreciation is expected to support reported revenue growth. Investors will watch whether operating leverage and mix benefits can sustain the margin expansion seen in recent quarters. The quarter is also being viewed in the context of a sharp share-price run-up during April to June 2026.

Board meeting and dividend consideration

The company’s board meeting is scheduled for July 24, 2026, to consider the audited financial results. The same meeting will also consider a recommendation on dividend for FY 2026-2027, as stated in the provided notice context. For markets, the timing matters because it sets the near-term catalyst for both numbers and any capital-allocation update. Any commentary around margins, working capital, and segment mix is likely to be closely parsed alongside the financial statements.

Earnings call at 5 PM IST: participation details

Laurus Labs has scheduled a conference call on July 24, 2026, at 5:00 PM IST to discuss the Q1 FY27 financial results. The call is to be hosted by DAM Capital Advisors, and will include a performance presentation followed by a Q&A session. Dial-in access is available for India and overseas participants, including Singapore, Hong Kong, the USA, and the UK. This call is expected to be a key venue for any management commentary on CDMO scale-up and margin drivers.

Rupee depreciation: a clear tailwind for export realisations

The rupee depreciation cited in the preview is one of the clearest near-term variables for Laurus’ reported topline. The currency is described as having moved from ₹83-84 in Q1 FY26 to ₹94.50-97.00 in Q1 FY27, implying a 12-14% year-on-year depreciation. For an export-led business, that can lift rupee-denominated revenue even without an equivalent change in underlying volumes. Investors will still look for confirmation that the currency benefit is not masking any demand softness in specific product lines.

Margins in focus: can Q4 levels sustain?

EBITDA margins are expected to show expansion versus the Q1 FY26 base of 24.85%. The preview notes the possibility that margins could remain near the Q4 FY26 level of 28.27%, supported by operating leverage and a favourable CDMO product mix. Management has also been quoted elsewhere in the provided material as expecting FY27 EBITDA margins to be “maintained or improved,” though quantified revenue guidance was not provided. In FY26, EBITDA margin improved to 26.8%, with Q4 margin referenced as “nearly 29%” in another section.

Segment signals: CDMO growth versus ARV API erosion

The central operating question remains how quickly CDMO growth can offset pressure in legacy areas. The antiretroviral (ARV) API segment is said to be facing revenue erosion, but its diluting share in total revenue is expected to moderate the impact. Meanwhile, CDMO is positioned as the main growth driver, and management commentary in the material points to CDMO revenues being projected to reach 50% of overall sales by FY2030. Any segment-level disclosure and mix commentary in Q1 FY27 will be important for understanding the durability of margin gains.

Working capital: inventory build is a monitorable

Working capital is highlighted as a key monitorable, particularly after an ₹141 crore inventory build in Q4 FY26. The text indicates total inventories reached a higher level in Q4 FY26, but the absolute inventory figure is not fully provided. Investors typically track whether inventory growth is linked to higher throughput, customer stocking, or slower-moving products, and whether it normalises in subsequent quarters. The Q1 FY27 balance sheet and cash flow commentary will therefore be an important companion to the P&L.

What the recent numbers show: FY26 and Q4 FY26 snapshot

Laurus reported FY26 revenue of ₹6,813 crore, up 23% year-on-year, driven mainly by CDMO and supported by its Affordable Medicines (Generics) portfolio. FY26 EBITDA was ₹1,826 crore, up 64% year-on-year, with an EBITDA margin of 26.8%; FY26 net profit was ₹889 crore, and diluted EPS was ₹16.4. For Q4 FY26, revenue was ₹1,812 crore, described as the company’s highest quarterly revenue in its presentation, with EBITDA of ₹523 crore and an EBITDA margin of 28.9%; Q4 net profit was ₹279 crore, and diluted EPS was ₹5.2. Operating cash flow for FY26 was cited at ₹1,624 crore versus ₹602 crore in FY25.

Q1 FY27 expectations versus Q1 FY26 base

A preview estimate attributed to Uniresearch puts Q1 FY27 revenue at ₹2,063 crore (+31.4% YoY) and PAT at ₹243 crore (+50.0% YoY). The base quarter referenced for comparison is Q1 FY26 revenue of ₹1,570 crore and PAT of ₹162 crore. Separately, the Q1 FY26 press note cited EBITDA of ₹389 crore and an EBITDA margin of 24.8%, with gross margin of 59.4%. Market participants will reconcile these expectations with the company’s reported segment performance and any one-offs.

Share-price moves and valuation markers cited

The stock is described as having zoomed 53% in Q1 FY27 (April to June 2026), the sharpest quarterly rally in five years, and it hit a record high of ₹1,530.30 on the BSE. At 02:28 PM on Tuesday, the stock was quoted 1% higher at ₹1,518, while the BSE Sensex was at 76,730. Another data point in the material lists CMP at ₹1,529.8 and market cap at ₹82,647.38 crore, while a separate ranking snapshot states the stock trades at a P/E of 80.4 with market cap of ₹71,455. These differing market-cap figures appear in different parts of the supplied text and should be interpreted in that context.

Why this result matters for the broader CDMO narrative

Laurus operates 15 globally approved facilities, and FY26 results were positioned as being driven by CDMO expansion and improved mix. With the rupee weakening versus last year’s Q1 levels, the quarter provides a clean test of whether currency, mix, and operating leverage are moving together. At the same time, the continuing ARV API erosion and the working-capital trend remain key checks on the quality of growth. The earnings call should help clarify how management views demand visibility, product mix, and any near-term constraints.

Conclusion

Laurus Labs will report Q1 FY27 results on July 24, 2026, followed by an earnings call at 5 PM IST. The market’s main focus is on CDMO-led export growth, the benefit from the rupee’s 12-14% depreciation, and whether EBITDA margins can stay near recent highs. Updates on working capital after the ₹141 crore Q4 inventory build and any dividend recommendation for FY 2026-2027 will also be tracked. The company’s commentary during the call is expected to be the next confirmed checkpoint on margins, mix, and execution for FY27.